ThedaCare Developmental Screening within Well-Child Care - 3/10/2022 5:00 pm
This educational opportunity is based on the AAP policy statement on developmental screening (2020) is delivered virtually or onsite and is designed to promote the early identification of and timely referral for children with delays. Health care professionals learn about and receive copies of a validated developmental screening tool, Ages and Stages Questionnaire-3, and a validated autism-specific screening instrument, Modified Checklist for Autism in Toddlers-Revised with Follow-Up. In addition, community partners serving children with delays and their families will share information about their programs.
Intended Audience
This program is intended for physicians, nurses, nurse practitioners, physician assistants, and social workers who utilize these tools in their practice.
Learning Objectives
By participating in this activity members of the health care team will be able to:
- Outline the AAP recommendations on developmental surveillance and screening.
- Utilize the ASQ-3 and MCHAT-R/F screening tools.
- Develop at least one way to incorporate developmental screening into well-child care delivery in their care team's practice.
- Identify resource and referral options in the community for children with developmental delays and disabilities and their families
5:00 pm | CHAW Intro & Learning Objectives (3 min) |
5:03 pm | Why Developmental Screening? (10 min) |
5:13 pm |
|
5:28 pm |
|
5:38 pm | Implementation (10 min) |
5:48 pm | Resources & Next Steps (10 min) |
5:58 pm |
|
6:00 pm | Adjourn |
Policy on Disclosure
It is the policy of the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) to identify, mitigate and disclose all relevant financial relationships with ineligible companies* held by the speakers/presenters, authors, planners, and other persons who may influence content of this accredited continuing education (CE). In addition, speakers, presenters and authors must disclose any planned discussion of unlabeled/unapproved uses of drugs or devices during their presentation.
For this accredited continuing education activity all relevant financial relationships have been mitigated and detailed disclosures are listed here.
Name | Role | Financial Relationship Disclosures | Discussion of Unlabeled/Unapproved uses of drugs/devices in presentation? | COI completion date |
Geeta Wadhwani | Course Director, Medical Director | No relevant relationships with ineligible companies to disclose | No | 1/10/2022 |
Morgan Conti | Planner, Speaker/Author | No relevant relationships with ineligible companies to disclose | No | 1/7/2022 |
Diane Gerlach | Committee Member | No relevant relationships with ineligible companies to disclose | No | 1/10/2022 |
Anne Harris | Committee Member | No relevant relationships with ineligible companies to disclose | No | 1/6/2022 |
Cheryl Wendt | Committee Member | No relevant relationships with ineligible companies to disclose | No | 1/7/2022 |
Wendy Hein | Planner, Speaker/Author | No relevant relationships with ineligible companies to disclose | No | 2/4/2022 |
Colleen Lane | Planner, Speaker/Author | No relevant relationships with ineligible companies to disclose | No | 1/6/2022 |
Allison Lourash | Planner, Speaker/Author | No relevant relationships with ineligible companies to disclose | No | 1/10/2022 |
Tim Markle | Planner, Speaker/Author | No relevant relationships with ineligible companies to disclose | No | 1/6/2022 |
Sara Scott | Accreditation Specialist | No relevant relationships with ineligible companies to disclose | No | 12/6/2021 |
Zara Bischoff | Speaker/Author | No relevant relationships with ineligible companies to disclose | No | 1/21/2022 |
Samantha Cortez | Speaker/Author | No relevant relationships with ineligible companies to disclose | No | 1/14/2022 |
Kim Fenendael | Speaker/Author | No relevant relationships with ineligible companies to disclose | No | 2/22/2022 |
Bradley Holman | Speaker/Author | No relevant relationships with ineligible companies to disclose | No | 1/12/2022 |
Vicki Mulvey | Speaker/Author | No relevant relationships with ineligible companies to disclose | No | 2/17/2022 |
Kelli Palecek | Speaker/Author | No relevant relationships with ineligible companies to disclose | No | 2/11/2022 |
Kristel Princl | Speaker/Author | No relevant relationships with ineligible companies to disclose | No | 2/22/2022 |
Dawn Stark | Speaker/Author | No relevant relationships with ineligible companies to disclose | No | 1/24/2022 |
*Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on, patients. The ACCME does not consider providers of clinical services directly to patients to be ineligible entities.
Accreditation Statement In support of improving patient care, this activity has been planned and implemented by the University of Wisconsin–Madison ICEP and Children's Health Alliance of Wisconsin. The University of Wisconsin–Madison ICEP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. | |
American Medical Association (AMA) The University of Wisconsin–Madison ICEP designates this virtual live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. American Nurses Credentialing Center (ANCC) The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 1.0 ANCC contact hours. Continuing Education Units (CEUs) The University of Wisconsin–Madison ICEP, as a member of the University Professional & Continuing Education Association (UPCEA), authorizes this program for 0.1 CEUs or 1.0 hours. |
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC Contact Hours
- 1.00 University of Wisconsin–Madison Continuing Education Hours
- 1.00 Approved for AMA PRA Category 1 Credit™